Evaluation of Some Inflammtory Proteins and Immunological Parameters in Breast Cancer Patients Attending Oncology Clinic at American Cancer Hospital, Iho, Imo State
DOI:
https://doi.org/10.64229/bsww4q20Keywords:
Breast Cancer, Inflammorty Proteins, Immunological Parameters, Oncology ClinicAbstract
Breast cancer is associated with complex alterations in inflammatory and immunological parameters,. This study aimed to evaluate inflammatory proteins, immunological parameters in breast cancer patients attending the Oncology Clinic at American Cancer Clinic, Iho. The study population comprised seventy-five (75) histologically confirmed breast cancer patients and seventy-five (75) apparently healthy individuals without any known malignancy who served as the control group. Informed and written consent was sought and obtained from prospective study participants who are eligible for the study before collecting their samples. The blood samples were collected in plain tubes and serum obtained from the clotted blood was analyzed for CRP, IL-6, IgM, and IgG using appropriate immunoassay techniques. Data obtained in this study was analyzed using Statistical Package for Social Sciences (SPSS) version 21. The student independent t-test and one-way ANOVA were used to compare means across groups. Results were expressed as Mean ± standard deviation. Pearson’s correlation coefficient was employed to assess associations among parameters. Values with p<0.05 were considered statistically significant. The results showed that the mean values of CRP, IL-6, IgM and IgG were significantly higher (p=0.001) in newly diagnosed breast cancer patients (28.37 ± 9.57 mg/L, 35.69 ± 13.89 pg/mL, 1.84 ± 0.40 g/L, 14.89 ± 1.13 g/L) when compared to those on chemotherapy (20.97 ± 6.93 mg/L, 27.59 ± 7.64 pg/mL, 1.14 ± 0.22 g/L, 12.38 ± 0.93 g/L), post-surgery breast cancer patients on chemo (15.28 ± 4.76 mg/L, 15.00 ± 4.63 pg/mL, 1.12 ± 0.32 g/L, 11.04 ± 1.35 g/L) and controls (9.27 ± 8.16 mg/L, 8.51 ± 11.38 pg/mL, 1.61 ± 0.46 g/L, 13.19 ± 1.41 g/L). In conclusion, breast cancer is associated with significant alterations in inflammatory and immunological profiles, especially in newly diagnosed patients due to immune deregulations likely linked to tumor progression and treatment response but improved with chemotherapy and surgery.
References
[1]Wang, Y., Peng, D., Zhou, X., Hu, W. and Li, F. (2024). Treatments and prognosis of the breast ductal carcinoma in situ. Clinical Breast Cancer, 24(2):122–130.
[2]Chen, J., Wei, Y., Yang, W., Huang, Q., Chen, Y., Zeng, K. and Chen, J. (2022). IL-6: The link between inflammation, immunity and breast cancer. Frontiers in Oncology, 12(2):903800.
[3]Fan, H., Wang, X., Li, W., Shen, M., Wei, Y., Zheng, H. and Kang, Y. (2020). ASB13 inhibits breast cancer metastasis through promoting SNAI2 degradation and relieving its transcriptional repression of YAP. Genes and Development, 34(19–20):1359–1372.
[4]Harwansh, R. K. and Deshmukh, R. (2020). Breast cancer: An insight into its inflammatory, molecular, pathological and targeted facets with update on investigational drugs. Critical Reviews in Oncology/Hematology, 154, 103070.
[5]Kanbayashi, C. and Iwata, H. (2025). Update on the management of ductal carcinoma in situ of the breast: Current approach and future perspectives. Japanese Journal of Clinical Oncology, 55(1):4–11.
[6]Hutajulu, S. H., Astari, Y. K., Ucche, M., Kertia, N., Subronto, Y. W., Paramita, D. K., Choridah, L., Ekaputra, E., Widodo, I., Suwardjo, S., Hardianti, M. S., Taroeno-Hariadi, K. W., Purwanto, I. and Kurnianda, J. (2025). Prognostic significance of C-reactive protein (CRP) and albumin-based biomarker in patients with breast cancer receiving chemotherapy. PeerJ, 13(2):e19319.
[7]Agnoli, C., Grioni, S., Pala, V., Allione, A., Matullo, G., Gaetano, C. D., Tagliabue, G., Sieri, S. and Krogh, V. (2017). Biomarkers of inflammation and breast cancer risk: A case-control study nested in the EPIC-Varese cohort. Scientific Reports, 7(1):12708.
[8]Katsura, C., Ogunmwonyi, I., Kankam, H. K. and Saha, S. (2022). Breast cancer: Presentation, investigation and management. British Journal of Hospital Medicine, 83(2):1–7.
[9]Cserni, G. (2020). Histological type and typing of breast carcinomas and the WHO classification changes over time. Pathologica, 112(1):25–41.
[10]Ryser, M. D., Lange, J., Inoue, L. Y. T., O'Meara, E. S., Gard, C., Miglioretti, D. L., Bulliard, J. L., Brouwer, A. F., Hwang, E. S. and Etzioni, R. B. (2022). Estimation of breast cancer overdiagnosis in a U.S. breast screening cohort. Annals of Internal Medicine, 175(4):471–478.
[11]Sang, Y. B., Yang, H., Lee, W. S., Lee, S. J., Kim, S. G., Cheon, J., Kang, B., Kim, C. W., Chon, H. J. and Kim, C. (2022). High serum levels of IL-6 predict poor responses in patients treated with pembrolizumab plus axitinib for advanced renal cell carcinoma. Cancers, 14(23):5985
[12]De La Cruz-Vargas, J. A., Roldán-Arbieto, L., Malpartida Palomino, R., Ferrer Ponce, D., Fernández Anccas, C., Correa López, L., Beltrán Gárate, B. E. and Vela Ruiz, J. M. (2024). Inflammatory markers related to survival in breast cancer patients: Peru. The International Journal of Biological Markers, 39(4):277–283.
[13]Araoye, M.O. (2004) Sample Size Determination in Research Methodology with Statistics for Health and Social Sciences. Nathadex Publishers, Ilorin, 115-121.
[14]Farshid, G., Ibbetson, S. J., Pradhan, M., Henry, L., Manton, N. D., Dubowsky, A. and Poplawski, N. K. (2025). Clinical, histological and receptor profiles of invasive breast cancer and ductal carcinoma in situ in females with germline pathogenic variants in PTEN and implications for germline testing. Pathology, 57(1):72–80.
[15]Hart, P. C., Rajab, I. M., Alebraheem, M. and Potempa, L. A. (2020). C-reactive protein and cancer—Diagnostic and therapeutic insights. Frontiers in Immunology, 11(3):595835.
[16]Mikkelsen, M. K., Lindblom, N. A. F., Dyhl-Polk, A., Juhl, C. B., Johansen, J. S. and Nielsen, D. (2022). Systematic review and meta-analysis of C-reactive protein as a biomarker in breast cancer. Critical Reviews in Clinical Laboratory Sciences, 59(7):480–500.
[17]Siegel, R. L., Miller, K. D., Wagle, N. S. and Jemal, A.. (2023). Cancer Statistics, 2023. CA: A Cancer Journal for Clinicians, 73(1):17–48.
[18]Zucker, A., Winter, A., Lumley, D., Karwowski, P., Jung, M. K. and Kao, J. (2020). Prognostic role of baseline neutrophil-to-lymphocyte ratio in metastatic solid tumors. Molecular and Clinical Oncology, 13(4):25
[19]Hirano, T. (2021). IL-6 in inflammation, autoimmunity and cancer. International Immunology, 33(3):127–148.
[20]Weckmann, G., Kiel, S., Chenot, J. F. and Angelow, A. (2023). Association of anemia with clinical symptoms commonly attributed to anemia—Analysis of two population-based cohorts. Journal of Clinical Medicine, 12(3):921.
[21]Zhou, Q., Dong, J., Sun, Q., Lu, N., Pan, Y. and Han, X. (2021). Role of neutrophil-to-lymphocyte ratio as a prognostic biomarker in patients with breast cancer receiving neoadjuvant chemotherapy: A meta-analysis. BMJ Open, 11(9):e047957.
[22]Park, S. J., Park, J. Y., Shin, K., Hong, T. H., Kim, Y., Kim, I. H. and Lee, M. (2024). The role of pretreatment serum interleukin 6 in predicting short-term mortality in patients with advanced pancreatic cancer. Biomedicines, 12(4):903.
[23]Bruni, D., Angell, H. K. and Galon, J. (2020). The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy. Nature Reviews Cancer, 20(11):662–680.
[24]Plebani, M. (2023). Why C-reactive protein is one of the most requested tests in clinical laboratories? Clinical Chemistry and Laboratory Medicine, 61(9):1540–1545.
[25]Rakoczy, K., Kaczor, J., Sołtyk, A., Szymańska, N., Stecko, J., Drąg-Zalesińska, M. and Kulbacka, J. (2024). The immune response of cancer cells in breast and gynecologic neoplasms. International Journal of Molecular Sciences, 25(11):6206.
[26]Zhu, S., Yi, M., Wu, Y., Dong, B. and Wu, K. (2021). Roles of tumor-associated macrophages in tumor progression: Implications on therapeutic strategies. Experimental Hematology and Oncology, 10(1):60.
[27]Adedokun, B., Ademola, A., Makumbi, T., Odedina, S., Agwai, I., Ndom, P., Gakwaya, A., Ogundiran, T., Ojengbede, O., Huo, D. and Olopade, O. I. (2023). Unawareness of breast cancer family history among African women. The Pan African Medical Journal, 45(3):188.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Amaobi Rosecollet Ngozi, Nwanjo Harrison, Edward Ukamaka (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
